Everolimus is mainly used clinically to prevent rejection after kidney transplantation and heart transplantation. Its mechanism of action mainly includes immunosuppressive effect, anti-tumor effect, anti-viral effect, and vascular protective effect. It is often used in combination with other immunosuppressants such as cyclosporine to reduce toxicity.
Compared with sirolimus, everolimus has superior pharmacokinetics.
Everolimus was first developed by the Swiss company Novartis and is available in tablets and dispersible tablets. Trade name Certican. It was first launched in Sweden in 2003 and has fully occupied the European market in 2006.
In addition, in addition to renal cell carcinoma, everolimus is also being studied in neuroendocrine tumors, lymphomas, other cancers, and tuberous sclerosis, either as a single agent or in combination with existing cancers. Treatment methods are combined. As an investigational drug, the safety and efficacy of everolimus have not been fully established in the oncology field and is now in the clinical trial phase, which is conducted under strict control and monitoring. These trials are designed to better understand the compound's potential benefits and corresponding risks. Due to the uncertainty of clinical trials, it is not yet guaranteed that everolimus can be commercially sold globally as a drug for oncology indications.
Everolimus is currently (2010) approved under the trade name Certican. It is used to prevent organ rejection in heart and kidney transplant patients. Certican was first approved in Europe in 2003 and is currently (2010) available in more than 60 countries.